Seattle biotech Atossa Therapeutics eyes acquisition of unnamed company
July 11, 2022 at 17:25 PM EDT
Atossa has paid $3 million for exclusive rights to negotiate the deal. The target company focuses on a form of cancer treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.